The melanoma revolution: from UV carcinogenesis to a new era in therapeutics.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25414302.
- Also identified by DOI 10.1126/science.1253735 and PMC identifier 4701046.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Melanoma, the deadliest form of skin cancer, is an aggressive disease that is rising in incidence. Although melanoma is a historically treatment-resistant malignancy, in recent years unprecedented breakthroughs in targeted therapies and immunotherapies have revolutionized the standard of care for patients with advanced disease. Here, we provide an overview of recent developments in our understanding of melanoma risk factors, genomics, and molecular pathogenesis and how these insights have driven advances in melanoma treatment. In addition, we review benefits and limitations of current therapies and look ahead to continued progress in melanoma prevention and therapy. Remarkable achievements in the field have already produced a paradigm shift in melanoma treatment: Metastatic melanoma, once considered incurable, can now be treated with potentially curative rather than palliative intent.
Medical subject headings
- Carcinogenesis
- Melanocytes
- Melanoma
- Molecular Targeted Therapy
- Skin Neoplasms